Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 3/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22799749 | 0.80 | EPHX1 (0.51) | CD274PDCD1EPHX1LMNASMN1; SMN2 | |
| SCHEMBL18378750 | 0.79 | TRPA1 (0.39) | CD274PDCD1HCRTR1HCRTR2WNT3A | |
| SCHEMBL607544 | 0.74 | CD274 (0.71) | CD274PDCD1GABRA1GABRB2EPHX1 | |
| SCHEMBL19726596 | 0.73 | CA2 (0.38) | CD274PDCD1GABRA1GABRB2HCRTR1 | |
| SCHEMBL18367725 | 0.73 | GABRA1 (0.38) | CD274PDCD1GABRA1GABRB2HCRTR1 | |
| SCHEMBL19589423 | 0.72 | ROCK2 (0.44) | CD274PDCD1TRPA1 | |
| SCHEMBL24359881 | 0.71 | BRD4 (0.47) | CD274PDCD1 | |
| SCHEMBL5318296 | 0.71 | TRPA1 (0.41) | SMN1; SMN2WNT3ATRPA1 | |
| SCHEMBL18367730 | 0.70 | CD274 (0.70) | CD274PDCD1EPHX1 | |
| SCHEMBL13368903 | 0.70 | PDCD1 (0.50) | CD274PDCD1GABRA1GABRB2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210061831-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061831-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | CD274 2821/4885PDCD1 3404/4885GABRA1 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.